James P. Beltzer
Human Genome Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James P. Beltzer.
Cancer Gene Therapy | 2001
Matthew A. Spear; Xandra O. Breakefield; James P. Beltzer; Deborah E. Schuback; Ralph Weissleder; Francisco S Pardo; Robert Charles Ladner
Phage display techniques rely on nearly random oligonucleotide sequences inserted into the protein III filament binding protein of an Escherichia coli filamentous phage M13 to generate a library of phage that express more than 10 7 different peptides. Phage that expresses a sequence having high affinity for a specific molecule, cell, or tissue can then be isolated through selective binding and recovery. Selected phage cannot only be used as gene transfer vectors in themselves, but the small peptide epitopes can be sequenced and potentially recombined into the attachment proteins of viral vectors, or used by themselves to target other therapeutic agents and diagnostic imaging radiolabels. Most phage display selections are carried out against purified and/or fixed protein targets, raising concerns as to the relevance of the selected epitopes. We have selected phage from the CMTI library against viable U87-MG human malignant glioma cells using a derivation of biopanning. The library, which initially contained phage expressing 2×10 7 different epitope sequences, collapsed after four rounds of selection such that 42% of recovered clones expressed a consensus sequence. Selective binding to viable adherent U87-MG cells was subsequently demonstrated under physiologic conditions at 167% (±27%) unselected phage using a novel, viable enzyme-linked immunosorbent assay technique. In comparison, there was no difference in binding to control 9L rat gliosarcoma, PANC-1 human pancreatic adenocarcinoma, T98-MG human malignant glioma, or AST-4 human malignant glioma cells of selected compared to unselected phage. Using polymerase chain reaction, the epitope was recovered with flanking unique restriction sites for recombination into a herpes simplex virus type-1 vector. This study demonstrates and discusses optimized methodologies for using phage display to target viable cells. Cancer Gene Therapy (2001) 8, 506–511
Archive | 2001
James P. Beltzer; Tony J. Fleming; Robert Charles Ladner; M. Daniel Potter
Archive | 2001
Charles R. Wescott; James P. Beltzer; Aaron K. Sato
Journal of Molecular Recognition | 2005
Tony J. Fleming; Meena Sachdeva; Marko Delic; James P. Beltzer; Charles R. Wescott; Mary Devlin; Robert C. Lander; Viktor Roschke; David M. Hilbert; Daniel J. Sexton
Archive | 2005
James P. Beltzer; M. Potter; Tony J. Fleming; Craig A. Rosen; Marilou Potter
Archive | 2000
Charles R. Wescott; Shrikumar A. Nair; Andrew Kolodziej; James P. Beltzer
Archive | 2010
James P. Beltzer; M. Daniel Potter; Tony J. Fleming
Archive | 2001
James P. Beltzer; Daniel M. Potter; Tony J. Fleming; Robert Charles Ladner
Archive | 2001
Charles R. Wescott; James P. Beltzer; Aaron K. Sato
Archive | 2001
James P. Beltzer; Daniel M. Potter; Tony L. Fleming; Craig A. Rosen